Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell

L Banner; L Hosler; M Parris; M Gelder; Martin Laimer; Johann Bauer; A South; N Nikbakht

Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell

L Banner, L Hosler, M Parris, M Gelder, Martin Laimer, Johann Bauer, A South, N Nikbakht

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	S105-S105
Journal	JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume	143
Issue number	5
Publication status	Published - 2023
Event	1st International Societies for Investigative Dermatology Meeting - Tokyo, JAPAN Duration: 12 May 2023 → 13 May 2023

Cite this

Banner, L., Hosler, L., Parris, M., Gelder, M., Laimer, M., Bauer, J., South, A., & Nikbakht, N. (2023). Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell. JOURNAL OF INVESTIGATIVE DERMATOLOGY , 143(5), S105-S105.

Banner, L ; Hosler, L ; Parris, M et al. / Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell. In: JOURNAL OF INVESTIGATIVE DERMATOLOGY 2023 ; Vol. 143, No. 5. pp. S105-S105.

@article{77e9b4010b5841ab885ce27f85bbcf61,

title = "Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell",

author = "L Banner and L Hosler and M Parris and M Gelder and Martin Laimer and Johann Bauer and A South and N Nikbakht",

year = "2023",

language = "English",

volume = "143",

pages = "S105--S105",

journal = "JOURNAL OF INVESTIGATIVE DERMATOLOGY ",

issn = "0022-202X",

publisher = "Elsevier ",

number = "5",

note = "1st International Societies for Investigative Dermatology Meeting ; Conference date: 12-05-2023 Through 13-05-2023",

}

Banner, L, Hosler, L, Parris, M, Gelder, M, Laimer, M , Bauer, J, South, A & Nikbakht, N 2023, 'Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell', JOURNAL OF INVESTIGATIVE DERMATOLOGY , vol. 143, no. 5, pp. S105-S105.

Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell. / Banner, L; Hosler, L; Parris, M et al.
In: JOURNAL OF INVESTIGATIVE DERMATOLOGY , Vol. 143, No. 5, 2023, p. S105-S105.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell

AU - Banner, L

AU - Hosler, L

AU - Parris, M

AU - Gelder, M

AU - Laimer, Martin

AU - Bauer, Johann

AU - South, A

AU - Nikbakht, N

PY - 2023

Y1 - 2023

M3 - Abstract (Journal)

SN - 0022-202X

VL - 143

SP - S105-S105

JO - JOURNAL OF INVESTIGATIVE DERMATOLOGY

JF - JOURNAL OF INVESTIGATIVE DERMATOLOGY

IS - 5

T2 - 1st International Societies for Investigative Dermatology Meeting

Y2 - 12 May 2023 through 13 May 2023

ER -

Banner L, Hosler L, Parris M, Gelder M, Laimer M , Bauer J et al. Oral rigosertib demonstrates preliminary efficacy in the treatment of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell. JOURNAL OF INVESTIGATIVE DERMATOLOGY . 2023;143(5):S105-S105.